rs149007883 — NFKBIZ NFKBIZ p.Gly102Ala

Rare protective missense variant in the NF-kB inhibitor zeta gene that reduces Th17-driven autoimmune thyroid inflammation and lowers hypothyroidism risk

See your personal result for NFKBIZ

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

NFKBIZ p.Gly102Ala — A Rare Shield Against Autoimmune Thyroid Disease

Your thyroid is one of the most common targets of the immune system turning against itself. Hashimoto's thyroiditis11 Hashimoto's thyroiditis
The most prevalent autoimmune thyroid disease globally, in which immune cells progressively destroy thyroid tissue, causing hypothyroidism in millions affects up to 10% of women and is the leading cause of hypothyroidism in iodine-sufficient countries. A 2025 large-scale genetic study revealed that a rare variant in NFKBIZ — the gene encoding NF-κB inhibitor zeta (IκBζ) — provides meaningful protection against this autoimmune attack.

The Mechanism

NFKBIZ encodes IκBζ (IkappaBzeta)22 IκBζ (IkappaBzeta)
A nuclear protein of the IκB family that, unlike classical IκBs which sequester NF-κB in the cytoplasm, acts inside the nucleus as a selective transcriptional coactivator for specific NF-κB target genes. IκBζ is indispensable for the differentiation of Th17 cells33 Th17 cells
A subset of pro-inflammatory CD4+ helper T cells that produce interleukin-17 (IL-17), a cytokine central to many autoimmune diseases. It cooperates with nuclear receptors RORγt and RORα to bind directly to the regulatory region of the IL17A gene, amplifying IL-17 production.

The rs149007883 variant substitutes glycine (GGG codon) for alanine (GCG) at position 102 of the IκBζ protein. This glycine-to-alanine change occurs in the N-terminal region of the protein before the conserved ankyrin-repeat domain. Adding a methyl side chain where there was none alters the local backbone geometry, likely reducing the efficiency with which IκBζ assembles into transcriptional complexes at the IL17A locus. The net result is a partial dampening of Th17 differentiation and IL-17 output — enough to reduce the thyroid-directed autoimmune pressure without abrogating normal immune defense.

The Evidence

The protective association was identified in a landmark genome-wide meta-analysis by Rand et al. 202544 genome-wide meta-analysis by Rand et al. 2025
Rand SA et al. Genome-wide association study and polygenic risk prediction of hypothyroidism. Nature Genetics, 2025. This study analysed 113,393 hypothyroidism cases and 1,065,268 controls — the largest genetic study of hypothyroidism to date. Among the 350 significant loci identified, the NFKBIZ p.Gly102Ala variant (C allele) emerged as protective with an odds ratio of approximately 0.83, meaning C allele carriers have roughly 17% lower odds of hypothyroidism compared to GG individuals. The study highlighted that many hypothyroidism risk loci regulate immune cell counts and inflammatory pathways, consistent with the Th17-axis biology of NFKBIZ.

The mechanistic rationale is well-supported by a foundational mouse knockout study by Okamoto et al. 201055 mouse knockout study by Okamoto et al. 2010
Okamoto K et al. IkappaBzeta regulates T(H)17 development by cooperating with ROR nuclear receptors. Nature, 2010, which demonstrated that NFKBIZ-null mice cannot generate Th17 cells and are resistant to experimental autoimmune disease. Separately, Konca Degertekin et al. 201666 Konca Degertekin et al. 2016
Konca Degertekin C et al. Circulating Th17 cytokine levels are altered in Hashimoto's thyroiditis. Cytokine, 2016 showed that IL-17 and IL-23 levels are significantly elevated in patients with Hashimoto's thyroiditis (p=0.041 for IL-17 vs controls), directly linking the Th17 axis — which NFKBIZ governs — to human autoimmune thyroid pathology.

Practical Actions

This variant is rare (C allele frequency ~0.9% in Europeans, essentially absent elsewhere), so the GC genotype is found in roughly 1 in 100 people of European descent. Carriers of the C allele have a moderately reduced lifetime risk of autoimmune hypothyroidism. This does not eliminate thyroid risk, but it is a meaningful biological buffer.

For GC carriers, the protective signal primarily justifies reduced vigilance for early hypothyroidism screening compared to individuals with other autoimmune risk variants. The effect operates through reduced Th17 activity, so conditions that amplify Th17 responses — such as vitamin D deficiency, gut dysbiosis, or chronic iodine excess — could theoretically partially offset this genetic advantage.

Homozygous CC carriers are so rare (<0.003% globally) that they would represent the most extreme dampening of IκBζ-driven Th17 activity, though no clinical data exist for this genotype given the tiny sample sizes involved.

Interactions

NFKBIZ sits at the intersection of NF-κB signaling and Th17 biology. Its protective effect on autoimmune thyroid disease may compound with other immunomodulatory variants. The PTPN22 R620W variant (rs2476601) is a major risk factor for Hashimoto's thyroiditis via T-cell activation thresholds; individuals carrying both PTPN22 risk alleles and NFKBIZ protection (GC/CC) may experience partial offset of PTPN22-mediated risk. CTLA4 rs3087243 is another autoimmune thyroid locus affecting T-cell co-stimulation — the two pathways (co-stimulation threshold via CTLA4 vs Th17 effector output via NFKBIZ) are mechanistically additive rather than redundant.

Genotype Interpretations

What each possible genotype means for this variant.

GG Standard Th17 Activity Normal

Standard NF-κB inhibitor zeta function and typical autoimmune thyroid risk

The GG genotype encodes the canonical glycine-102 form of IκBζ. In this configuration, IκBζ efficiently cooperates with RORγt and RORα to drive IL-17A transcription in activated CD4+ T cells. The Th17 axis plays a documented role in autoimmune thyroid disease, including Hashimoto's thyroiditis, where elevated IL-17 and IL-23 correlate with thyroid antibody titers and gland inflammation. Carrying GG does not mean high risk — it simply means you lack the partial Th17 dampening that the C allele confers.

CG Partial Th17 Dampening Beneficial

One protective NFKBIZ allele — moderately reduced Th17-driven autoimmune thyroid risk

The heterozygous GC genotype produces a mix of wild-type (Gly102) and variant (Ala102) IκBζ protein. Alanine's methyl side chain subtly alters the local protein geometry near the N-terminus, likely reducing the efficiency of IκBζ assembly into transcriptional activation complexes at the IL17A promoter. The result is a partial, rather than complete, suppression of Th17 output — matching the codominant pattern and the moderate (17%) protective effect observed in the GWAS. This degree of Th17 dampening is enough to shift long-term autoimmune risk without impairing normal immune responses to infection.

The protective effect is specific to Th17-mediated autoimmune risk. NFKBIZ also participates in innate immune responses to bacterial lipopolysaccharide via NF-κB. The Gly102Ala substitution primarily affects the Th17 transcriptional co-activation function, so carriers are not expected to have increased susceptibility to bacterial infections.

CC Strong Th17 Dampening Beneficial

Two protective NFKBIZ alleles — strongest genetic dampening of Th17-driven autoimmune thyroid risk

The homozygous CC genotype means all IκBζ protein produced carries the Ala102 variant. If the heterozygous state partially reduces Th17 transcriptional output, the homozygous state would be expected to suppress this output further under a codominant model. The rarity of CC means it was not distinguished from GC in the 2025 GWAS analysis (too few CC homozygotes in 113,393 cases to separate), so effect size estimates are extrapolated from the overall allele dose-response pattern rather than directly observed.

Because IκBζ also participates in innate immune NF-κB responses beyond Th17 differentiation, complete functional loss of the Gly102 form may theoretically affect a broader set of immune processes, but the Ala102 substitution is not a loss-of-function mutation — it is a missense variant with partial functional modification, not protein elimination.